ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1093

Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias
Abstract Number: 2579

Risk of End-Stage Renal Disease Among Patients with Lupus Nephritis on GLP-1 Receptor Agonists: A Retrospective Cohort Study
Abstract Number: 1439

Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
Abstract Number: 2009

Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes
Abstract Number: 1336

Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Abstract Number: 1401

Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
Abstract Number: 1102

Risk of Mortality and Major Cardiovascular-Kidney Outcomes in Patients with Tophaceous versus Non-Tophaceous Gout
Abstract Number: 2614

Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
Abstract Number: 1127

Risk of Ocular Inflammatory Conditions in Patients with Autoimmune Diseases: A Retrospective Study Using the National Inpatient Sample
Abstract Number: 0719

Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease
Abstract Number: 1867

RNA Polymerase III Specific CD8+ T Cells at the Interface Between Scleroderma and Cancer
Abstract Number: 0969

Role and Mechanism of the Wnt3a-FZD5 Pathway in Regulating the Transformed Intermediate State of Alveolar Epithelial Cells Involved in Pulmonary Fibrosis in Systemic Sclerosis
Abstract Number: 2225

Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
Abstract Number: 2131

Role of LECT2 in the Regulation of Bone Metabolism In Vitro and In Vivo
Abstract Number: 1831

Role of Long Non-Coding RNA H19 in Mediating Skin Fibrosis in Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].